About 36 million people around the world are now infected with HIV. Researchers say this would be a "historic" event for HIV if it were to show some efficacy. It's been modified to better fight the virus in the region around South Africa.
Fauci claims that even a moderately effective vaccine will have a significant effect in reducing the numbers of HIV infections. The trial is slated to begin in November 2016, pending regulatory approval.
The vaccine will be tested in a study, the first in seven years to test a vaccine against HIV, the National Institutes of Health, which is funding the study, said on Monday. "We are seeing that countries are getting on the Fast-Track-more than 18 million people are on life-saving HIV treatment and country after country is on track to virtually eliminate HIV transmission from mother to child".
A new clinical trial is underway in South Africa on an experimental vaccine that could safely prevent HIV, the virus that causes AIDS. The new trial, to be conducted at 15 sites across South Africa, where more than 1,000 people become infected with HIV every day, aims to test whether it will provide greater and more sustained protection than the RV144 regimen.
The Post notes that about 5,400 people-who must be HIV-negative, sexually active and between the ages of 18 and 35-are being recruited for the trial.
The aim of the HIV clinical trial is to reduce the number of HIV infections among the test subjects through the use of a vaccine.
The study is excepted to yield results in 2020, according to the AP.
Co-chairing the protocol with Dr. Due to these troubling numbers, an effective vaccine has always been sought after by researchers. It looked at a vaccine candidate called RV144.
However, it did prove one thing: HIV can be prevented with a vaccine, however modest the success rate.
In addition to the NIAID, the two pharma companies and the HVTN, the P5 brings together the Bill & Melinda Gates Foundation (BMGF), the South African Medical Research Council and the US Military HIV Research Programme. In the decades that have spanned since HIV first made global media headlines during the mid-1980s, only four vaccines have undergone testing. Additionally, the protein subunit vaccine in HVTN 702 is combined with MF59 (also supplied by GSK), a different adjuvant than the one used in RV144, in the hope of generating a more robust immune response. The exact trial involves treating the participants with five injections of the vaccine over a period of one year. The participants will be randomly assigned to either receive the actual vaccine or just a placebo.